← Back to Clinical Trials
Recruiting NCT01604395
Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
Trial Parameters
Condition Growth Hormone Deficiency
Sponsor LG Chem
Study Type OBSERVATIONAL
Phase N/A
Enrollment 6,000
Sex ALL
Min Age 2 Years
Max Age N/A
Start Date 2012-01
Completion 2032-12-31
Brief Summary
The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).
Eligibility Criteria
Inclusion Criteria: * short stature children aged 2 years or more * children with GHD,TS, CRF, SGA or ISS * written informed consent from the person, person's parent or legal guardian